Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daunorubicin Citrate

FDA-approved product (injectable, liposomal, injection), marketed as Daunoxome, Cerubidine, Daunorubicin Hydrochloride.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Daunorubicin Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myeloid leukemia
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
Open Daunorubicin Citrate in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daunorubicin Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

    NCT05554419 · start 2026-07-01

    Registered record
    Registry ID
    NCT05554419
    Conditions
    Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia
    Interventions
    Azacitidine; Bone Marrow Aspiration and Biopsy; Cytarabine; Echocardiography Test; Liposome-encapsulated Daunorubicin-Cytarabine; Multigated Acquisition Scan; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2026-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy +1 more
    InterventionAzacitidine; Bone Marrow Aspiration and Biopsy; Cytarabine; Echocardiography Test +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

    NCT07664839 · start 2026-07-01

    Registered record
    Registry ID
    NCT07664839
    Conditions
    Acute Myeloid Leukemia; NPM1 Mutation; IDH1 Mutation; IDH2 Mutation
    Interventions
    VEN combined with azacitidine; Cytarabine plus Daunorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2032-05-31
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; NPM1 Mutation; IDH1 Mutation; IDH2 Mutation
    InterventionVEN combined with azacitidine; Cytarabine plus Daunorubicin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

    NCT07486479 · start 2026-03-10

    Registered record
    Registry ID
    NCT07486479
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Mitoxantrone Hydrochloride Liposome; Venetoclax; Azacitidine; Idarubicin; Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-10
    Completion
    2027-12-31
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionMitoxantrone Hydrochloride Liposome; Venetoclax; Azacitidine; Idarubicin +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

    NCT07076186 · start 2025-10-02

    Registered record
    Registry ID
    NCT07076186
    Conditions
    Uterine Leiomyosarcoma
    Interventions
    Trabectedin; Doxorubicin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-02
    Completion
    2029-12-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Leiomyosarcoma
    InterventionTrabectedin; Doxorubicin Hydrochloride
    PhasePhase 2
    Registry statusRecruiting

  • Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    NCT07152041 · start 2025-03-28

    Registered record
    Registry ID
    NCT07152041
    Conditions
    Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventions
    olverembatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2030-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
    Interventionolverembatinib
    PhasePhase 3
    Registry statusRecruiting

  • Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

    NCT05996185 · start 2024-10-09

    Registered record
    Registry ID
    NCT05996185
    Conditions
    T Cell Lymphoma; T-cell Lymphoma
    Interventions
    Mogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2027-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma; T-cell Lymphoma
    InterventionMogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    PhasePhase 2
    Registry statusRecruiting

  • A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

    NCT05886049 · start 2024-06-20

    Registered record
    Registry ID
    NCT05886049
    Conditions
    Acute Myeloid Leukemia; Acute Myeloid Leukemia With KMT2A Rearrangement; Acute Myeloid Leukemia With NPM1 Mutation; Secondary Acute Myeloid Leukemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cytarabine; Daunorubicin; Multigated Acquisition Scan; Revumenib; Transthoracic Echocardiography Test
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-06-20
    Completion
    2027-12-31
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Myeloid Leukemia With KMT2A Rearrangement; Acute Myeloid Leukemia With NPM1 Mutation; Secondary Acute Myeloid Leukemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cytarabine +4 more
    PhasePhase 1
    Registry statusRecruiting

  • A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

    NCT05406401 · start 2022-07-14

    Registered record
    Registry ID
    NCT05406401
    Conditions
    Lymphoma, Large B-Cell, Diffuse (DLBCL)
    Interventions
    Zilovertamab Vedotin; Cyclophosphamide; Doxorubicin; Rituximab; Rituximab Biosimilar; Prednisone; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-07-14
    Completion
    2029-04-26
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large B-Cell, Diffuse (DLBCL)
    InterventionZilovertamab Vedotin; Cyclophosphamide; Doxorubicin; Rituximab +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

    NCT05913427 · start 2022-06-08

    Registered record
    Registry ID
    NCT05913427
    Conditions
    Adrenocortical Carcinoma
    Interventions
    Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-06-08
    Completion
    2027-06-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenocortical Carcinoma
    InterventionEtoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

    NCT05092360 · start 2022-01-10

    Registered record
    Registry ID
    NCT05092360
    Conditions
    Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    Interventions
    Nemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD); Paclitaxel; Topotecan; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-01-10
    Completion
    2025-05-08
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    InterventionNemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD) +3 more
    PhasePhase 3
    Registry statusTerminated

  • The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

    NCT04877821 · start 2021-09-15

    Registered record
    Registry ID
    NCT04877821
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Sintilimab; Anlotinib; Nab paclitaxel; Carboplatin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-15
    Completion
    2026-03-10
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionSintilimab; Anlotinib; Nab paclitaxel; Carboplatin +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of N9 Chemotherapy in Children With Neuroblastoma

    NCT04947501 · start 2021-06-22

    Registered record
    Registry ID
    NCT04947501
    Conditions
    Neuroblastoma; Pediatric Cancer
    Interventions
    Cyclophosphamide; Topotecan; Vincristine; Doxorubicin; Ifosfamide; Etoposide; Carboplatin; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2021-06-22
    Completion
    2027-06-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Pediatric Cancer
    InterventionCyclophosphamide; Topotecan; Vincristine; Doxorubicin +4 more
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

    NCT04908787 · start 2021-06-11

    Registered record
    Registry ID
    NCT04908787
    Conditions
    Ovarian Cancer
    Interventions
    BD0801; Paclitaxel; Placebo; Topotecan; doxorubicin liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2024-10-11
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionBD0801; Paclitaxel; Placebo; Topotecan +1 more
    PhasePhase 3
    Registry statusCompleted

  • The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

    NCT04753177 · start 2021-01-28

    Registered record
    Registry ID
    NCT04753177
    Conditions
    The Neoadjuvant Therapy
    Interventions
    Ribocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-01-28
    Completion
    2024-01-28
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Neoadjuvant Therapy
    InterventionRibocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

    NCT04498793 · start 2020-09

    Registered record
    Registry ID
    NCT04498793
    Conditions
    HER2-negative Breast Cancer
    Interventions
    Tislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09
    Completion
    2022-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-negative Breast Cancer
    InterventionTislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin +1 more
    PhasePhase 2
    Registry statusUnknown